Sun Pharma Q4 results 2026: Pharma major Sun Pharmaceutical Industries on Friday, 22 May, reported a 26.24% year-on-year (YoY) rise in its consolidated profit to ₹2,714.03 crore for the January-March quarter of the financial year 2026 (Q4FY26). In the same quarter of the previous financial year, Sun Pharma’s profit was ₹2,149.88 crore.
However, on a sequential or quarter-on-quarter (QoQ) basis, Sun Pharma’s consolidated profit fell 19.44%, as in Q3FY26, the pharma company’s profit was ₹3,368.81 crore.
Total revenue from operations for the quarter under review rose 12.8% YoY but fell 5.9% QoQ to ₹14,611.79 crore.
In Q4FY25, Sun Pharma’s revenue was ₹12,958.84 crore, while in Q3FY26, it was ₹15,520.54 crore.
EBITDA for the quarter increased by 6.4% YoY to ₹3,955 crore, but margin eased to 27.1% from 28.7% YoY.
During the quarter, the company’s sales stood at ₹14,559.8 crore, clocking a growth of 13.6% YoY.
For the full financial year (FY26), Sun Pharma’s net profit increased by 5% to ₹11,479.4 crore, while sales stood at ₹58,220.1 crore, up 11.9% YoY. EBITDA for the year jumped 16.1% YoY to ₹17,731.4 crore, while EBITDA margin rose to 30.3% from 29% YoY.
Meanwhile, Sun Pharma’s board recommended a final dividend of ₹5 per share of ₹l each. This is in addition to the interim dividend of ₹11 per share paid in FY26, taking the total dividend for FY26 to ₹16 per share, the same as FY25.
Sun Pharma said India formulations grew by 14.8%, led by the CVD, CNS, Gastro, and Ortho segments, while US formulations declined marginally to $459 million in Q4FY26.
With 14% growth in FY26, India formulations now forms 33% of total consolidated sales. US formulations formed 29% of total consolidated sales in FY26. Emerging markets grew by 13.6% to $1.27 billion in FY26.
ended 2.43% lower at ₹1,845.20 on the BSE on Friday.
Disclaimer: This story is for educational purposes only and does not constitute investment advice. The views and recommendations expressed are those of individual analysts or broking firms, not Mint. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary.